1,261 results on '"Schwartz, Gary K."'
Search Results
302. Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy
303. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas
304. Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry
305. Phase I Trial of the Cyclin-Dependent Kinase Inhibitor and Protein Kinase C Inhibitor 7-Hydroxystaurosporine in Combination With Fluorouracil in Patients With Advanced Solid Tumors
306. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma
307. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma
308. Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials
309. Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors
310. Phase II Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol Administered to Patients With Advanced Gastric Carcinoma
311. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma
312. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT)
313. Oncology urgent care to decrease unnecessary emergency room visits.
314. Comparison of attitudes and beliefs about cancer clinical trial enrollment between physicians, research staff, and cancer patients.
315. Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo
316. Abstract CT028: Drug-drug interaction potential of EZH2 inhibitor tazemetostat (TAZ)
317. Abstract 292: PTC596 combination therapy for sarcoma
318. Abstract 1842: A novel therapeutic approach to overcome resistance to glutaminase inhibition inNF1driven malignant peripheral nerve sheath tumors MPNST
319. Abstract 214: Preclinical evaluation of a novel MET antibody-drug conjugate in uveal melanoma models
320. Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers.
321. Clinical utility and reimbursement for expanded genomic panel testing in adult oncology.
322. Correlates of overall survival (OS) in metastatic uveal melanoma (mUM) and a randomized trial of cabozantinib (cabo) versus chemotherapy (chemo).
323. Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other soft tissue sarcomas.
324. Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma
325. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face
326. Sorafenib for Advanced and Refractory Desmoid Tumors
327. Exceptional Response to Dacarbazine in Uterine Leiomyosarcoma With Homozygous BRCA2 Deletion Highlights the Role of Homologous Recombination in Response to DNA Damage From Alkylating Agents
328. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma
329. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
330. Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target.
331. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil + doxorubicin + high dose methotrexate + leucovorin) with oral uridine rescue
332. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells
333. Defining the invasive phenotype of proximal gastric cancer cells
334. Edatrexate in patients with soft tissue sarcoma: activity in malignant fibrous histiocytoma
335. Characterization of cell lines established from human gastric-esophageal adenocarcinomas: biologic phenotype and invasion potential
336. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion
337. The relevance of drug sequence in combination chemotherapy
338. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors
339. Abstract 1329: Combination treatment with CB-839 and romidepsin induces apoptosis and suppresses cell viability in preclinical models of chondrosarcoma
340. Abstract 2940: Chemosensitization of cholangiocarcinoma by guadecitabine
341. Abstract 5784: A novel ERK inhibitor in the treatment of uveal melanoma
342. YouTube Videos as a Source of Information About Clinical Trials: Observational Study
343. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
344. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
345. Clonal evolution of uveal melanoma metastases.
346. Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.
347. Phase 1b/2 study of olaratumab plus gemcitabine and docetaxel for the treatment of advanced soft tissue sarcoma (STS) (ANNOUNCE 2): Phase 1b results.
348. Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism.
349. Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.
350. A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.